TITLE

QLT to discontinue trial of punctal plug delivery system for allergic conjunctivitis

PUB. DATE
March 2011
SOURCE
Ocular Surgery News;3/25/2011, Vol. 29 Issue 6, p58
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the plan of QLT to discontinue the trial on olopatadine punctual plug delivery system for allergic conjunctivitis due to its failure to generate definitive clinical results.
ACCESSION #
86439114

 

Related Articles

  • LoteprednoI a first-line therapy for SAC. Krader, Cheryl Guttman; McCabe, Craig // Optometry Times;Feb2011, Vol. 3 Issue 2, p26 

    The article discusses the efficacy of loteprednol etabonate ophthalmic suspension 0.2% as a treatment for seasonal allergic conjunctivitis (SAC) including its corticosteroid action to reduce prostaglandin production, and inhibit the release of histamine.

  • A Powerful Option for the Treatment of Bacterial Conjunctivitis. Asbell, Penny A. // Ophthalmology Times;6/15/2014, Vol. 39 Issue 12, p1 

    Appropriate treatment of bacterial conjunctivitis serves to shorten the clinical course of disease, reduce symptoms, abbreviate the period of contagion, and reduce time lost from school or work. Furthermore, treatment with an effective agent can reduce the slight risk for more serious...

  • Anti-allergic ophthalmic drugs in general practice: which, why and when? Mohamed, N.; Smit, D. P. // South African Family Practice;Jul/Aug2013, Vol. 55 Issue 4, p313 

    Ocular allergies present in many different guises. They may vary from self-limiting episodes of acute allergic conjunctivitis, to potentially sight-threatening chronic conditions, such as vernal keratoconjunctivitis. This article provides a brief description of the different ocular allergic...

  • Epinastine dosing boosts adherence. Charters, Lynda; Milner, Mark S. // Optometry Times;Feb2011, Vol. 3 Issue 2, p25 

    The article discusses the efficacy of epinastine treatment for allergic conjunctivitis. Optometrists prescribe epinastine hydrochloride ophthalmic solution 0.05% or Elestat for the relief of ocular itching and the improvement of other symptoms such as hyperemia, chemosis, and lid-swelling....

  • A critical look at ocular allergy drugs. Titi, Mark Joseph // American Family Physician;6/1/1996, Vol. 53 Issue 8, p2637 

    Presents a critical look at topical ocular allergy drugs used for the treatment of allergic conjunctivitis. Approach in using chemotherapeutic protocols; Efficacy studies; Antihistamine-vasoconstrictors preparations; Lodoxamide; Ketorolac tromethamine; Levocabastine; Topical ocular corticosteroids.

  • Bepotastine yields lasting relief. Krader, Cheryl Guttman; O'Brien, Terrence P. // Optometry Times;Feb2011, Vol. 3 Issue 2, p32 

    The article offers information on the efficacy of bepotastine for reducing ocular itching in patients with allergic conjunctivitis. It presents the findings of clinical studies using the conjunctival allergen challenge (CAC) model wherein patients were randomly treated with bepotastine besilate...

  • Olopatadine: Once-daily dosing benefit. Charters, Lynda; Scoper, Stephen V. // Optometry Times;Feb2011, Vol. 3 Issue 2, p33 

    The article discusses information on the efficacy of olopatadine for improving symptoms of allergic conjunctivitis. Majority of patients prescribed with olopatadine hydrochloride ophthalmic solution 0.2% report high compliance to the treatment due to its once-a-day dosing requirement. A quality...

  • Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: A randomized, placebo-controlled, natural exposure, clinical trial. Carr, Warner W.; Nayak, Anjuli S.; Ratner, Paul H.; Gow, James A.; McNamara, Timothy R.; Williams, Jon I.; for the Bepotastine Besilate Ophthalmic Solution 1.5% (Bepreve) Study Group // Allergy & Asthma Proceedings;May/Jun2013, Vol. 34 Issue 3, p247 

    Allergic conjunctivitis (AC) affects an estimated 20% of the population in the Western world, with a large fraction suffering due to seasonal or perennial allergen exposures. Bepotastine besilate ophthalmic solution (BBOS) 1.5%, a dual-acting histamine (H1) receptor antagonist and mast cell...

  • EFFECT OF FUCITHALMIC AND SOFINOX EYE DROPS ON EXPERIMENTAL ALLERGIC CONJUNCTIVITIS IN RATS. SATYAM, SHAKTA MANI; ADIGA, SHALINI; CHOGTU, BHARTI; BAIRY, K. LAXMINARAYANA; PIRASANTHAN, RAJADURAI; VAISHNAV, RAJDIP LALIT // International Journal of Pharmacy & Pharmaceutical Sciences;2014, Vol. 6 Issue 11, p458 

    Objective: To investigate the therapeutic effect of Fucithalmic 1%, Sofinox 0.5% and 1% eye drops against an IgE-mediated allergic conjunctivitis model in Wistar rats. Methods: IgE-mediated allergic conjunctivitis was induced by ovalbumin antigen challenge. Allergic conjunctivitis induced...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics